香港，2025 年 12 月 30 日（GLOBE NEWSWIRE）—— Visionary Holdings Inc.（“GV” 或 “公司”），一家在纳斯达克上市的技术驱动跨国企业（纳斯达克：GV），今天宣布其全资子公司 Visionary Health Technology Group Limited（“ GV 香港” ），已正式任命 蔡文轩女士 为 GV 香港的首席执行官，立即生效。
与此同时，GV 香港在中国南京成立了 一家全资子公司，主要致力于销售执行和市场开发。这一里程碑标志着 GV 正式从战略定位转向积极的现场收入生成。
加强领导以推动市场执行
蔡女士在市场扩展、品牌商业化和建立销售组织方面拥有近二十年的丰富经验，涵盖医疗保健和企业管理领域。她对中国高端医疗市场有深刻的理解，并在将高层战略转化为可扩展的销售成果方面有着良好的历史记录。
作为 GV 香港的首席执行官，蔡女士将专注于：
<ul>
<li>建立和领导区域销售和市场团队；</li>
<li>执行 GV 在 细胞再生和美学治疗 领域的市场进入策略；</li>
<li>扩大机构、渠道和战略合作伙伴关系；</li>
<li>驱动可持续的收入增长并增强销售可见性。</li>
</ul>
销售基础设施现已全面部署
新成立的南京实体将作为 前线商业平台，处理区域销售运营和渠道开发。结合 GV 在香港的亚太平台，公司已完成涵盖战略、产品和销售执行的全面整合商业结构。这一发展表明 GV 的商业化努力现在已积极运营并具备可扩展性。
管理层评论
Visionary Holdings 首席执行官侯西勇评论道：
“在过去几个月中，GV 执行了一条有序的路线图——进入细胞再生和美学治疗领域，完成技术许可，并推出我们的产品组合。我们现在已经完成了最关键的组成部分：一个有能力且以执行为导向的销售组织。
随着我们在南京建立本地化销售实体，我们相信 GV 的商业化努力已超越概念规划，现在已积极运营并具备可扩展性。
我们对蔡女士建立高绩效销售团队的能力以及将市场战略转化为我们股东可见的商业成果充满信心。”
从战略进入到商业实现
GV 最近的里程碑形成了一个连贯且渐进的增长叙事：
<ul>
<li>在 细胞再生和美学治疗 领域的战略进入，包括与干细胞相关的技术和治疗解决方案；</li>
<li>完成全球技术许可和整合；</li>
<li>启动多样化的产品和治疗组合；</li>
<li>部署本地化销售和市场执行团队以完成商业化循环。</li>
</ul>
随着领导层、产品和销售基础设施的全面对接，GV 已准备好利用对先进细胞基础和美学解决方案日益增长的需求。
关于 Visionary Holdings Inc.
Visionary Holdings Inc.（纳斯达克：GV）是一家技术驱动的跨国企业，专注于创新教育、人工智能应用和高科技医疗解决方案。公司总部位于加拿大多伦多，通过其在北美和亚洲的子公司运营，推动技术进步、跨境创新和全球健康转型。
关于前瞻性声明的警示说明
本新闻稿包含根据 1934 年证券交易法第 21E 条和 1995 年美国私人证券诉讼改革法定义的前瞻性声明。这些前瞻性声明可以通过诸如 “将”、“期望”、“预期”、“未来”、“打算”、“计划”、“相信”、“估计”、“目标”、“展望”、“目标” 和类似术语来识别。这些声明基于管理层当前的期望和当前市场及运营条件，并涉及已知或未知的风险、不确定性和其他因素，所有这些因素都难以预测并超出 GV 的控制范围，可能导致 GV 的实际结果、表现或成就（包括其预期收益的人民币/美元价值）与前瞻性声明中包含或暗示的预期结果存在重大不利差异。有关这些及其他风险、不确定性或因素的进一步信息包含在 GV 向美国证券交易委员会提交的文件中，相关文件可在 www.sec.gov 获取。GV 不承担因新信息、未来事件或其他原因而更新任何前瞻性声明的义务，除非法律要求。
联系方式：
Visionary Holdings Inc.
投资者关系
电子邮件：IR@visionary.holdings
<img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56Z3pPU00zTXpNNE5Ua3lJekl6TURVM056WT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56Z3pPU00zTXpNNE5Ua3lJekl6TURVM056WT0"/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGU3Yjg3ZGMtMTllZC00OWE5LThiYTktNDQ0OGM0YWVmZGQ3LTEzMTczMjYtMjAyNS0xMi0zMC1lbg==/tiny/Visionary-Holdings-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGU3Yjg3ZGMtMTllZC00OWE5LThiYTktNDQ0OGM0YWVmZGQ3LTEzMTczMjYtMjAyNS0xMi0zMC1lbg==/tiny/Visionary-Holdings-Inc-.png"/>

Visionary Holdings Inc.（纳斯达克代码：GV）已任命蔡文轩女士为其子公司 Visionary Health Technology Group Limited 的首席执行官，任命立即生效。该公司还在中国南京建立了一个新的销售实体，以增强市场执行力。这一举措标志着公司从战略规划转向在细胞复兴和美容治疗领域的积极创收。GV 希望借助已建立的全面商业结构，利用亚洲对先进医疗解决方案日益增长的需求

HONG KONG, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (“GV” or the “Company”), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited（“ GV Hong Kong” ）, has official appointed Ms. Wenxuan Cai as Chief Executive Officer of GV Hong Kong, effective immediately.
<div class="lb-trans">香港，2025 年 12 月 30 日（GLOBE NEWSWIRE）—— Visionary Holdings Inc.（“GV” 或 “公司”），一家在纳斯达克上市的技术驱动跨国企业（纳斯达克：GV），今天宣布其全资子公司 Visionary Health Technology Group Limited（“ GV 香港” ），已正式任命 蔡文轩女士 为 GV 香港的首席执行官，立即生效。
</div>In parallel, the GV Hong Kong has established a new wholly owned subsidiary in Nanjing, China, dedicated primarily to sales execution and market development. This milestone marks GV’s formal transition from strategic positioning to active on-the-ground revenue generation.
<div class="lb-trans">与此同时，GV 香港在中国南京成立了 一家全资子公司，主要致力于销售执行和市场开发。这一里程碑标志着 GV 正式从战略定位转向积极的现场收入生成。
</div>Strengthening Leadership to Drive Market Execution
<div class="lb-trans">加强领导以推动市场执行
</div>Ms. Cai joins the Company with nearly two decades of extensive experience in market expansion, brand commercialization, and building sales organization across healthcare and enterprise management sectors. She possesses a deep understanding of China’s premium healthcare market and a proven history of translating high-level strategy into scalable sales outcomes.
<div class="lb-trans">蔡女士在市场扩展、品牌商业化和建立销售组织方面拥有近二十年的丰富经验，涵盖医疗保健和企业管理领域。她对中国高端医疗市场有深刻的理解，并在将高层战略转化为可扩展的销售成果方面有着良好的历史记录。
</div>As CEO of GV Hong Kong, Ms. Cai will focus on:
<div class="lb-trans">作为 GV 香港的首席执行官，蔡女士将专注于：
</div><ul>
<li>Building and leading regional sales and marketing teams;</li>
<li>Executing go-to-market strategies for GV’s offerings in the fields of cellular rejuvenation and aesthetic treatment;</li>
<li>Expanding institutional, channel, and strategic partnerships;</li>
<li>Driving sustainable revenue growth and enhancing sales visibility.</li>
</ul>
<div class="lb-trans"><ul>
<li>建立和领导区域销售和市场团队；</li>
<li>执行 GV 在 细胞再生和美学治疗 领域的市场进入策略；</li>
<li>扩大机构、渠道和战略合作伙伴关系；</li>
<li>驱动可持续的收入增长并增强销售可见性。</li>
</ul>
</div>Sales Infrastructure Now Fully Deployed
<div class="lb-trans">销售基础设施现已全面部署
</div>The newly established Nanjing entity will serve as frontline commercial platforms, handling regional sales operations and channel development. Combined with GV’s Asia-Pacific platform in Hong Kong, the Company has completed a fully integrated commercial structure spanning strategy, products, and sales execution. This development signals that GV’s commercialization efforts are now actively operational and scalable.
<div class="lb-trans">新成立的南京实体将作为 前线商业平台，处理区域销售运营和渠道开发。结合 GV 在香港的亚太平台，公司已完成涵盖战略、产品和销售执行的全面整合商业结构。这一发展表明 GV 的商业化努力现在已积极运营并具备可扩展性。
</div>Management Commentary
<div class="lb-trans">管理层评论
</div>Xiyong Hou, Chief Executive Officer of Visionary Holdings, commented:
<div class="lb-trans">Visionary Holdings 首席执行官侯西勇评论道：
</div>“Over the past several months, GV has executed a disciplined roadmap—entering the fields of cellular rejuvenation and aesthetic treatment, completing technology licensing, and launching our product portfolio. We have now finalized the most critical component: a capable and execution-driven sales organization.
<div class="lb-trans">“在过去几个月中，GV 执行了一条有序的路线图——进入细胞再生和美学治疗领域，完成技术许可，并推出我们的产品组合。我们现在已经完成了最关键的组成部分：一个有能力且以执行为导向的销售组织。
</div>With the establishment of our localized sales entity in Nanjing, we believe GV’s commercialization efforts have moved beyond conceptual planning and are now actively operational and scalable.
<div class="lb-trans">随着我们在南京建立本地化销售实体，我们相信 GV 的商业化努力已超越概念规划，现在已积极运营并具备可扩展性。
</div>We have strong confidence in Ms. Cai’s ability to build high-performance sales teams and to translate market strategy into tangible commercial results for our shareholders”
<div class="lb-trans">我们对蔡女士建立高绩效销售团队的能力以及将市场战略转化为我们股东可见的商业成果充满信心。”
</div>From Strategic Entry to Commercial Realization
<div class="lb-trans">从战略进入到商业实现
</div>GV’s recent milestones form a coherent and progressive growth narrative:
<div class="lb-trans">GV 最近的里程碑形成了一个连贯且渐进的增长叙事：
</div><ul>
<li>Strategic entry into the fields of cellular rejuvenation and aesthetic treatment, including stem-cell-related technologies and therapeutic solutions;</li>
<li>Completion of global technology licensing and integration;</li>
<li>Launch of a diversified product and treatment portfolio;</li>
<li>Deployment of localized sales and market execution teams to complete the commercialization loop.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 细胞再生和美学治疗 领域的战略进入，包括与干细胞相关的技术和治疗解决方案；</li>
<li>完成全球技术许可和整合；</li>
<li>启动多样化的产品和治疗组合；</li>
<li>部署本地化销售和市场执行团队以完成商业化循环。</li>
</ul>
</div>With leadership, products, and sales infrastructure now fully aligned, GV is positioned to capitalize on growing demand for advanced cellular-based and aesthetic solutions across Asia.
<div class="lb-trans">随着领导层、产品和销售基础设施的全面对接，GV 已准备好利用对先进细胞基础和美学解决方案日益增长的需求。
</div>About Visionary Holdings Inc.
<div class="lb-trans">关于 Visionary Holdings Inc.
</div>Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.
<div class="lb-trans">Visionary Holdings Inc.（纳斯达克：GV）是一家技术驱动的跨国企业，专注于创新教育、人工智能应用和高科技医疗解决方案。公司总部位于加拿大多伦多，通过其在北美和亚洲的子公司运营，推动技术进步、跨境创新和全球健康转型。
</div>Cautionary Note Regarding Forward-Looking Statements
<div class="lb-trans">关于前瞻性声明的警示说明
</div>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as &#34;will&#34;, &#34;expects&#34;, &#34;anticipates&#34;, &#34;future&#34;, &#34;intends&#34;, &#34;plans&#34;, &#34;believes&#34;, &#34;estimates&#34;, &#34;target&#34;, &#34;going forward&#34;, &#34;outlook,&#34; &#34;objective&#34; and similar terms. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV's control, which may cause GV's actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
<div class="lb-trans">本新闻稿包含根据 1934 年证券交易法第 21E 条和 1995 年美国私人证券诉讼改革法定义的前瞻性声明。这些前瞻性声明可以通过诸如 “将”、“期望”、“预期”、“未来”、“打算”、“计划”、“相信”、“估计”、“目标”、“展望”、“目标” 和类似术语来识别。这些声明基于管理层当前的期望和当前市场及运营条件，并涉及已知或未知的风险、不确定性和其他因素，所有这些因素都难以预测并超出 GV 的控制范围，可能导致 GV 的实际结果、表现或成就（包括其预期收益的人民币/美元价值）与前瞻性声明中包含或暗示的预期结果存在重大不利差异。有关这些及其他风险、不确定性或因素的进一步信息包含在 GV 向美国证券交易委员会提交的文件中，相关文件可在 www.sec.gov 获取。GV 不承担因新信息、未来事件或其他原因而更新任何前瞻性声明的义务，除非法律要求。
</div>Contacts:
<div class="lb-trans">联系方式：
</div>Visionary Holdings Inc.
<div class="lb-trans">Visionary Holdings Inc.
</div>Investor Relations
<div class="lb-trans">投资者关系
</div>Email: IR@visionary.holdings
<div class="lb-trans">电子邮件：IR@visionary.holdings
</div><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56Z3pPU00zTXpNNE5Ua3lJekl6TURVM056WT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNzgzOSM3MzM4NTkyIzIzMDU3NzY="/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGU3Yjg3ZGMtMTllZC00OWE5LThiYTktNDQ0OGM0YWVmZGQ3LTEzMTczMjYtMjAyNS0xMi0zMC1lbg==/tiny/Visionary-Holdings-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MGU3Yjg3ZGMtMTllZC00OWE5LThiYTktNDQ0OGM0YWVmZGQ3LTEzMTczMjYtMjAyNS0xMi0zMC1lbg==/tiny/Visionary-Holdings-Inc-.png"/>

Visionary Holdings (Nasdaq: GV) Appoints CEO of Health Technology Business, Establishes New Sales Entity in Nanjing to Accelerate Commercial Execution in China Market | GV Stock News

Visionary Holdings（纳斯达克代码：GV）任命健康科技业务的首席执行官，并在南京成立新的销售实体，以加速在中国市场的商业执行 | GV 股票新闻